Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
TAX-2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
TAX-2: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
JK-06 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
JK-06: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
mRNA-1769 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
mRNA-1769: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
STK-012 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
STK-012: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EO-2463 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
EO-2463: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HS-10375 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
HS-10375: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ORCA-010 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
ORCA-010: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RM-718 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
RM-718: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BA-1106 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BA-1106: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BMS-986458 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BMS-986458: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CP-506 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
CP-506: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ZL-1211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
ZL-1211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.